Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
- Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024
- Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year
- European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023, compared to the same periods prior year
- 该季度的毛利百分比为36％，比2024年第一财季增长1％
- 截至2023年9月30日的季度和六个月的总运营支出与去年同期相比有所下降
- 与去年同期相比，欧洲的收入在本季度增长了3％，在截至2023年9月30日的六个月中增长了13％
BOULDER, CO / ACCESSWIRE / November 13, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its second fiscal quarter ended September 30, 2023.
科罗拉多州博尔德/ACCESSWIRE/2023年11月13日/索诺玛制药公司（纳斯达克股票代码：SNOA）今天公布了截至2023年9月30日的第二财季的财务业绩，该公司是开发和生产稳定的次氯酸（HOCl）产品的全球医疗保健领导者，其应用范围广泛，包括伤口、眼部、口腔和鼻腔护理、皮肤病、足病、动物保健和无毒消毒剂。
"In the second quarter of our fiscal year 2024, we continued to reduce costs while maintaining our diligent efforts to expand sales and increase our presence in U.S. and international markets," said Amy Trombly, CEO of Sonoma. "Though our U.S. business saw a decline in consumer sales compared to the prior year, primarily due to softening demand for animal health care products, European revenues have continued to increase, and we see opportunities for further growth and demand for our products both in the U.S. and internationally."
索诺玛首席执行官艾米·特隆布利表示：“在2024财年的第二季度，我们继续降低成本，同时继续努力扩大销售并增加我们在美国和国际市场的影响力。”“尽管我们的美国业务的消费者销售额与去年相比有所下降，这主要是由于对动物保健产品的需求疲软，但欧洲的收入持续增长，我们看到了进一步增长的机会，也看到了美国和国际上对我们产品的需求和进一步增长的机会。”
Business Highlights
业务亮点
Sonoma continued to identify and meet customer needs by introducing new products and expanding distribution:
索诺玛继续通过推出新产品和扩大分销来识别和满足客户需求：
- On November 3, 2023, Sonoma launched its intraoperative pulse lavage irrigation treatment in the United States, a new application of its wound care technology developed in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. Hospitals in Europe began trial use of the pulse lavage irrigation treatment, containing Sonoma's Microcyn Technology, in September 2023.
- On August 15, 2023, Sonoma announced that Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel had received the National Eczema Association (NEA) Seal of Acceptance.
- On August 3, 2023, Sonoma announced the establishment of a Scientific Advisory Board, which will serve to inform the company's research and development activities, efforts to address areas of unmet need, and potential new areas of interest.
- 2023 年 11 月 3 日，索诺玛在美国推出了术中脉冲灌洗疗法，这是其伤口护理技术的新应用，旨在满足人们对可以预防感染和缩短愈合时间的无毒灌洗液的未得到满足的需求。欧洲的医院开始试用含有索诺玛的Microcyn的脉冲灌洗冲洗疗法 科技，2023年9月。
- 2023 年 8 月 15 日，索诺玛宣布 Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel 已获得全国湿疹协会 (NEA) 认可印章。
- 2023 年 8 月 3 日，索诺玛宣布成立科学顾问委员会，该委员会将为公司的研发活动、解决未满足需求领域的努力以及潜在的新兴趣领域提供信息。
Results for the Quarter Ended September 30, 2023
截至2023年9月30日的季度业绩
Total revenues for the quarter ended September 30, 2023 of $2.7 million decreased by $0.6 million, or 18%, as compared to $3.3 million for the same period last year. Revenues in the United States declined 39% primarily as a result of a decline in animal health over-the counter demand. Revenues in Europe increased 3% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues decreased in Asia and increased in Rest of World when compared to the same period last year. These revenues tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.
截至2023年9月30日的季度总收入为270万美元，与去年同期的330万美元相比减少了60万美元，下降了18％。美国的收入下降了39％，这主要是由于非处方需求导致动物健康下降。由于对索诺玛产品的需求增加，欧洲的收入与去年同期相比增长了3％。与去年同期相比，亚洲的收入下降，世界其他地区的收入增加。按季度来看，这些收入往往不稳定，这是因为客户下了更大但更少的订单，以便从数量折扣中受益，而在订购更大数量时，运费也会降低。
During the quarter ended September 30, 2023, Sonoma reported revenues of $2.7 million and cost of revenues of $1.7 million resulting in gross profit of $1.0 million, or 36% of revenue, compared to a gross profit of $1.5 million, or 46% of revenue in the same period last year. The decline is the result of changes in product mix and territories to which products are shipped.
在截至2023年9月30日的季度中，索诺玛公布的收入为270万美元，收入成本为170万美元，毛利为100万美元，占收入的36％，而去年同期的毛利为150万美元，占收入的46％。下降是产品组合和产品运送地区变化的结果。
Total operating expenses during the quarter ended September 30, 2023 were $2.2 million decreased as compared to the same period in the prior year.
截至2023年9月30日的季度，总运营支出与去年同期相比减少了220万美元。
Results for the Six Months Ended September 30, 2023
截至2023年9月30日的六个月业绩
Total revenues for the six months ended September 30, 2023 of $6.2 million decreased by $1.1 million, or 16%, as compared to $7.3 million for the same period last year. In the six months ended September 30, 2023, Sonoma sold machinery to a customer in Latin America for $750,000, which management expects to be a one-time event. Excluding that event, revenue for the six months ended September 30, 2023 decreased by $0.4 million, or 6%, compared to the same period last year. Revenues in the United States declined 24% primarily as a result of a decline in animal health over-the-counter demand. Revenues in Europe increased 13% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues decreased in Asia and Rest of World when compared to the same period last year. These revenues tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.
截至2023年9月30日的六个月中，总收入为620万美元，与去年同期的730万美元相比减少了110万美元，下降了16％。在截至2023年9月30日的六个月中，索诺玛以75万美元的价格向拉丁美洲的一位客户出售了机器，管理层预计这将是一次性的。不包括该事件，截至2023年9月30日的六个月收入与去年同期相比减少了40万美元，下降了6％。美国的收入下降了24％，这主要是由于动物健康非处方药需求的下降。由于对索诺玛产品的需求增加，欧洲的收入与去年同期相比增长了13％。与去年同期相比，亚洲和世界其他地区的收入有所下降。按季度来看，这些收入往往不稳定，这是因为客户下了更大但更少的订单，以便从数量折扣中受益，而在订购更大数量时，运费也会降低。
During the six months ended September 30, 2023, Sonoma reported revenues of $6.2 million and cost of revenues of $4.0 million resulting in gross profit of $2.2 million, or 36% of revenue, compared to a gross profit of $3.2 million, or 44% of revenue in the same period last year. The decline is the result of the sale of machinery in Latin America in 2022, which management expects to be a one-time event, and changes in product mix and territories to which products are shipped.
在截至2023年9月30日的六个月中，索诺玛公布的收入为620万美元，收入成本为400万美元，毛利为220万美元，占收入的36％，而去年同期的毛利为320万美元，占收入的44％。下降是2022年拉丁美洲机械销售的结果，管理层预计这将是一次性事件，以及产品组合和产品运送地区的变化。
Total operating expenses during the six months ended September 30, 2023 were $4.6 million decreased as compared to the same period in the prior year.
在截至2023年9月30日的六个月中，总运营支出与去年同期相比减少了460万美元。
Net loss for six months ended September 30, 2023 of $2.9 million increased by $1.0 million, or 52%, when compared to a net loss of $1.9 million for the six months ended September 30, 2023. The increase in net loss is primarily related to the one-time event equipment sale in Latin America in 2022 as well as the factors discussed above. EBITDA loss for the six months ended September 30, 2023 of $2.0 million increased $0.4 million, compared to an EBITDA loss of $1.6 million for the same period last year.
截至2023年9月30日的六个月净亏损为290万美元，增加了100万美元，增长了52％，而截至2023年9月30日的六个月净亏损为190万美元。净亏损的增加主要与2022年拉丁美洲的一次性活动设备销售以及上述因素有关。截至2023年9月30日的六个月中，息税折旧摊销前利润亏损200万美元，增加了40万美元，而去年同期的息税折旧摊销前利润亏损为160万美元。
As of September 30, 2023, Sonoma had cash and cash equivalents of $2.1 million.
截至2023年9月30日，索诺玛的现金及现金等价物为210万美元。
About Sonoma Pharmaceuticals, Inc.
关于索诺玛制药公司
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company has its corporate headquarters in Boulder, Colorado as well as manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact busdev@sonomapharma.com.
Sonoma Pharmicals是开发和生产稳定的次氯酸 (HOCl) 产品的全球医疗保健领导者，其应用范围广泛，包括伤口、眼睛、口腔和鼻腔护理、皮肤病、足病学、动物保健和无毒消毒剂。该公司的产品以安全有效的方式减少感染、瘙痒、疼痛、疤痕和有害的炎症反应。次氯酸 (HOCl) 的体外和临床研究表明，它具有令人印象深刻的止痒、抗菌、抗病毒和抗炎特性。索诺玛稳定的HOCl可立即缓解瘙痒和疼痛，杀死病原体并分解生物膜，不会刺痛或刺激皮肤，并为治疗区域的细胞充氧，帮助人体进行自然愈合。该公司的产品直接销售或通过合作伙伴在全球55个国家销售，该公司积极寻找新的分销合作伙伴。该公司的总部位于科罗拉多州的博尔德，在拉丁美洲也有制造业务。欧洲营销和销售总部位于荷兰鲁尔蒙德。更多信息可以在以下网址找到。如需合作机会，请联系 busdev@sonomapharma.com。
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
前瞻性陈述
除此处的历史信息外，根据1995年《私人证券诉讼改革法》的 “安全港” 条款，本新闻稿中陈述的事项具有前瞻性，包括有关索诺玛制药公司及其子公司（“公司”）的商业和技术进步以及未来财务业绩的声明。这些前瞻性陈述是通过使用 “继续”、“减少”、“发展”、“目标” 和 “扩大” 等词语来识别的。本新闻稿中的前瞻性陈述受公司业务固有的某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果发生变化，包括监管临床和指南开发可能发生变化、科学数据可能不足以满足监管标准或获得所需的监管许可或批准、临床结果可能无法在实际患者环境中复制、公司专利和专利申请提供的保护可能会受到质疑、无效或规避等风险其竞争对手，公司产品的可用市场将不如预期的那么大，公司的产品将无法进入一个或多个目标市场，收入将不足以满足公司的现金需求或为进一步发展提供资金，以及与最近的疫情和经济发展相关的不确定性、不同国家和城市的产品配方和多种不同的监管和营销要求，以及公司不时详细介绍的其他风险向其提交的文件证券交易委员会。除非法律要求，否则公司不承担任何更新这些前瞻性陈述的义务。
Sonoma Pharmaceuticals, Microcyn and Reliefacyn are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
索诺玛制药，Microcyn 和 Reliefacyn 是 Sonoma Pharmicals, Inc. 的商标或注册商标。所有其他商标和服务标志均为其各自所有者的财产。
Media and Investor Contact:
媒体和投资者联系人：
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
索诺玛制药有限公司
ir@sonomapharma.com
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
索诺玛制药有限公司和子公司
简明合并资产负债表
（以千计，股票金额除外）
| September 30, 2023 | March 31, 2023 | ||||
| (Unaudited) | |||||
ASSETS |
|||||
Current assets: |
|||||
Cash and cash equivalents |
$ | 2,137 | $ | 3,820 | |
Accounts receivable, net |
2,223 | 2,572 | |||
Inventories, net |
2,513 | 2,858 | |||
Prepaid expenses and other current assets |
4,395 | 4,308 | |||
Current portion of deferred consideration, net of discount |
248 | 240 | |||
Total current assets |
11,516 | 13,798 | |||
Property and equipment, net |
433 | 488 | |||
Operating lease, right of use assets |
350 | 418 | |||
Deferred tax asset |
840 | 949 | |||
Deferred consideration, net of discount, less current portion |
421 | 505 | |||
Other assets |
75 | 73 | |||
Total assets |
$ | 13,635 | $ | 16,231 | |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
Current liabilities: |
|||||
Accounts payable |
$ | 987 | $ | 841 | |
Accrued expenses and other current liabilities |
1,702 | 2,029 | |||
Deferred revenue |
101 | 100 | |||
Deferred revenue Invekra |
61 | 60 | |||
Short-term debt |
172 | 431 | |||
Operating lease liabilities |
216 | 256 | |||
Total current liabilities |
3,239 | 3,717 | |||
Long-term deferred revenue Invekra |
114 | 140 | |||
Withholding tax payable |
4,473 | 4,235 | |||
Operating lease liabilities, less current portion |
134 | 162 | |||
Total liabilities |
7,960 | 8,254 | |||
Commitments and Contingencies |
|||||
Stockholders' Equity |
|||||
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2023 and March 31, 2023, respectively, no shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively |
- | - | |||
Common stock, $0.0001 par value; 24,000,000 shares authorized at September 30, 2023 and March 31, 2023, respectively, 5,179,333 and 4,933,550 shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively |
1 | 5 | |||
Additional paid-in capital |
201,210 | 200,904 | |||
Accumulated deficit |
(192,416) | (189,514) | |||
Accumulated other comprehensive loss |
(3,120) | (3,418) | |||
Total stockholders' equity |
5,675 | 7,977 | |||
Total liabilities and stockholders' equity |
$ | 13,635 | $ | 16,231 | |
| 2023年9月30日 | 2023年3月31日 | ||||
| （未经审计） | |||||
资产 |
|||||
流动资产： |
|||||
现金和现金等价物 |
$ | 2,137 | $ | 3,820 | |
应收账款，净额 |
2,223 | 2,572 | |||
库存，净额 |
2,513 | 2,858 | |||
预付费用和其他流动资产 |
4,395 | 4,308 | |||
扣除折扣后的递延对价的当期部分 |
248 | 240 | |||
流动资产总额 |
11,516 | 13,798 | |||
财产和设备，净额 |
433 | 488 | |||
经营租赁、使用权资产 |
350 | 418 | |||
递延所得税资产 |
840 | 949 | |||
递延对价，扣除折扣，减去流动部分 |
421 | 505 | |||
其他资产 |
75 | 73 | |||
总资产 |
$ | 13,635 | $ | 16,231 | |
负债和股东权益 |
|||||
流动负债： |
|||||
应付账款 |
$ | 987 | $ | 841 | |
应计费用和其他流动负债 |
1,702 | 2,029 | |||
递延收入 |
101 | 100 | |||
递延收入 Invekra |
61 | 60 | |||
短期债务 |
172 | 431 | |||
经营租赁负债 |
216 | 256 | |||
流动负债总额 |
3,239 | 3,717 | |||
长期递延收入 Invekra |
114 | 140 | |||
应付预扣税 |
4,473 | 4,235 | |||
经营租赁负债，减去流动部分 |
134 | 162 | |||
负债总额 |
7,960 | 8,254 | |||
承付款和或有开支 |
|||||
股东权益 |
|||||
可转换优先股，面值0.0001美元；分别于2023年9月30日和2023年3月31日批准了714,286股，截至2023年9月30日和2023年3月31日分别没有发行和流通的股票 |
- | - | |||
普通股，面值0.0001美元；分别于2023年9月30日和2023年3月31日获得授权的24,000,000股，分别于2023年9月30日和2023年3月31日发行和流通的5,179,333股和4,933,550股股票 |
1 | 5 | |||
额外的实收资本 |
201,210 | 200,904 | |||
累计赤字 |
(192,416) | (189,514) | |||
累计其他综合亏损 |
(3,120) | (3,418) | |||
股东权益总额 |
5,675 | 7,977 | |||
负债和股东权益总额 |
$ | 13,635 | $ | 16,231 | |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
索诺玛制药有限公司和子公司
综合亏损简明合并报表
（以千计，每股金额除外）
（未经审计）
|
Three Months Ended September 30, |
Six Months Ended September 30, |
|||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenues |
$ | 2,731 | $ | 3,331 | $ | 6,158 | $ | 7,314 | ||||||||
Cost of revenues |
1,741 | 1,795 | 3,964 | 4,132 | ||||||||||||
Gross profit |
990 | 1,536 | 2,194 | 3,182 | ||||||||||||
Operating expenses |
||||||||||||||||
Research and development |
536 | 200 | 861 | 406 | ||||||||||||
Selling, general and administrative |
1,662 | 2,067 | 3,781 | 4,362 | ||||||||||||
Total operating expenses |
2,198 | 2,267 | 4,642 | 4,768 | ||||||||||||
Loss from operations |
(1,208 | ) | (731 | ) | (2,448 | ) | (1,586 | ) | ||||||||
Other expense, net |
(90 | ) | (186 | ) | (301 | ) | (253 | ) | ||||||||
Loss before income taxes |
(1,298 | ) | (917 | ) | (2,749 | ) | (1,839 | ) | ||||||||
Income tax expense |
(186 | ) | (100 | ) | (153 | ) | (65 | ) | ||||||||
Net loss |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | ||||
Net loss per share: basic and diluted |
$ | (0.29 | ) | $ | (0.33 | ) | $ | (0.57 | ) | $ | (0.61 | ) | ||||
Weighted-average number of shares: basic and diluted |
5,161 | 3,101 | 5,051 | 3,101 | ||||||||||||
Other comprehensive loss |
||||||||||||||||
Net loss |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | ||||
Foreign currency translation adjustments |
(213 | ) | (34 | ) | 298 | (99 | ) | |||||||||
Comprehensive loss |
$ | (1,697 | ) | $ | (1,051 | ) | $ | (2,604 | ) | $ | (2,003 | ) | ||||
| 三个月已结束 9月30日 |
六个月已结束 9月30日 |
|||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
收入 |
$ | 2,731 | $ | 3,331 | $ | 6158 | $ | 7,314 | ||||||||
收入成本 |
1,741 | 1,795 | 3,964 | 4,132 | ||||||||||||
毛利 |
990 | 1,536 | 2194 | 3,182 | ||||||||||||
运营费用 |
||||||||||||||||
研究和开发 |
536 | 200 | 861 | 406 | ||||||||||||
销售、一般和管理 |
1,662 | 2,067 | 3,781 | 4,362 | ||||||||||||
运营费用总额 |
2,198 | 2,267 | 4,642 | 4,768 | ||||||||||||
运营损失 |
(1,208 | ) | (731 | ) | (2,448) | ) | (1,586 | ) | ||||||||
其他费用，净额 |
(90) | ) | (186) | ) | (301 | ) | (253 | ) | ||||||||
所得税前亏损 |
(1,298 | ) | (917) | ) | (2,749) | ) | (1,839 | ) | ||||||||
所得税支出 |
(186) | ) | (100) | ) | (153 | ) | (65) | ) | ||||||||
净亏损 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | ||||
每股净亏损：基本亏损和摊薄后 |
$ | (0.29) | ) | $ | (0.33) | ) | $ | (0.57) | ) | $ | (0.61) | ) | ||||
加权平均股票数量：基本股数和摊薄后股数 |
5,161 | 3,101 | 5,051 | 3,101 | ||||||||||||
其他综合损失 |
||||||||||||||||
净亏损 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | ||||
外币折算调整 |
(213 | ) | (34) | ) | 298 | (99 | ) | |||||||||
综合损失 |
$ | (1,697) | ) | $ | (1,051) | ) | $ | (2,604) | ) | $ | (2,003) | ) | ||||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
索诺玛制药有限公司和子公司
公认会计准则衡量标准与非公认会计准则衡量标准的对账
（以千计）
（未经审计）
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
(1) Net loss adjusted for non-cash items and one-time events or EBITDA loss: |
|||||||||||||||
GAAP net loss as reported |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | |||
One-time event adjustment: |
|||||||||||||||
Equipment sale to customer in Latin America (one-time event) |
- | - | - | (400 | ) | ||||||||||
Non-cash adjustments: |
|||||||||||||||
Stock-based compensation |
130 | 113 | 307 | 327 | |||||||||||
Non-cash foreign exchange transaction losses |
108 | 189 | 367 | 256 | |||||||||||
Income tax expense |
186 | 100 | 153 | 65 | |||||||||||
Depreciation and amortization |
45 | 29 | 90 | 59 | |||||||||||
Non-GAAP net loss adjusted for non-cash items and one-time events or EBITDA loss |
$ | (1,015 | ) | $ | (586 | ) | $ | (1,985 | ) | $ | (1,597 | ) | |||
(2) Operating expenses minus non-cash expenses |
|||||||||||||||
GAAP operating expenses as reported |
$ | 2,198 | $ | 2,267 | $ | 4,642 | $ | 4,768 | |||||||
Non-cash adjustments: |
|||||||||||||||
Stock-based compensation |
(130 | ) | (113 | ) | (307 | ) | (327 | ) | |||||||
Depreciation and amortization |
(45 | ) | (29 | ) | (90 | ) | (59 | ) | |||||||
Non-GAAP operating expenses minus non-cash expenses |
$ | 2,023 | $ | 2,125 | $ | 4,245 | $ | 4,382 | |||||||
| 截至9月30日的三个月 | 截至9月30日的六个月 | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
(1) 根据非现金项目和一次性活动调整后的净亏损或息税折旧摊销前利润亏损： |
|||||||||||||||
报告的 GAAP 净亏损 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | |||
一次性活动调整： |
|||||||||||||||
向拉丁美洲客户销售设备（一次性活动） |
- | - | - | (400 | ) | ||||||||||
非现金调整： |
|||||||||||||||
基于股票的薪酬 |
130 | 113 | 307 | 327 | |||||||||||
非现金外汇交易损失 |
108 | 189 | 367 | 256 | |||||||||||
所得税支出 |
186 | 100 | 153 | 65 | |||||||||||
折旧和摊销 |
45 | 29 | 90 | 59 | |||||||||||
根据非现金项目和一次性事件调整后的非公认会计准则净亏损或息税折旧摊销前利润亏损 |
$ | (1,015) | ) | $ | (586 | ) | $ | (1,985) | ) | $ | (1,597 | ) | |||
(2) 运营费用减去非现金支出 |
|||||||||||||||
报告的 GAAP 运营支出 |
$ | 2,198 | $ | 2,267 | $ | 4,642 | $ | 4,768 | |||||||
非现金调整： |
|||||||||||||||
基于股票的薪酬 |
(130) | ) | (113) | ) | (307) | ) | (327) | ) | |||||||
折旧和摊销 |
(45) | ) | (29) | ) | (90) | ) | (59) | ) | |||||||
非公认会计准则运营费用减去非现金支出 |
$ | 2,023 | $ | 2,125 | $ | 4,245 | $ | 4,382 | |||||||
| (1) | Net loss adjusted for non-cash items and one-time events, or EBITDA loss, is a non-GAAP financial measure. The Company this as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes, sale of equipment to a Latin America company and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect normal direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
| (1) | 根据非现金项目和一次性事件调整后的净亏损或息税折旧摊销前利润亏损是非公认会计准则财务指标。该公司按公认会计原则报告净亏损减去折旧和摊销、股票薪酬、所得税、向拉丁美洲公司出售设备以及非现金外汇交易亏损。公司使用该衡量标准的目的是修改净亏损，使其仅反映这些支出，以反映衡量期内的正常直接现金交易。不应将非公认会计准则指标视为根据公认会计原则提出的财务指标的替代品。非公认会计准则指标与其他公司披露的非公认会计准则指标并不总是一致或可比的。 |
| (2) | Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
| (2) | 运营费用减去非现金支出是一项非公认会计准则财务指标。公司将运营费用减去非现金支出定义为GAAP报告的运营费用减去营业折旧和摊销以及基于股票的营业薪酬。公司使用该衡量标准来确定衡量期内涉及现金交易的总运营费用。不应将非公认会计准则指标视为根据公认会计原则列报的财务指标的替代品。非公认会计准则指标与其他公司披露的非公认会计准则指标并不总是一致或可比的。 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands)
(Unaudited)
索诺玛制药有限公司和子公司
与产品相关的收入明细表
（以千计）
（未经审计）
The following table shows our consolidated total revenue and revenue by geographic region for the three and six months ended September 30, 2023 and 2022:
下表显示了截至2023年9月30日和2022年9月30日的三个月和六个月中按地理区域划分的合并总收入和收入：
|
Three Months Ended September 30, |
||||||||||||||||
(In thousands) |
2023 | 2022 | $ Change | % Change | ||||||||||||
United States |
$ | 590 | $ | 973 | $ | (383 | ) | (39 | %) | |||||||
Europe |
1,201 | 1,170 | 31 | 3 | % | |||||||||||
Asia |
346 | 518 | (172 | ) | (33 | %) | ||||||||||
Latin America |
260 | 394 | (134 | ) | (34 | %) | ||||||||||
Rest of the World |
334 | 276 | 58 | 21 | % | |||||||||||
Total |
$ | 2,731 | $ | 3,331 | $ | (600 | ) | (18 | %) | |||||||
| 三个月已结束 9月30日 |
||||||||||||||||
（以千计） |
2023 | 2022 | $ Change | % 变化 | ||||||||||||
美国 |
$ | 590 | $ | 973 | $ | (383) | ) | (39) | %) | |||||||
欧洲 |
1,201 | 1,170 | 31 | 3 | % | |||||||||||
亚洲 |
346 | 518 | (172 | ) | (33) | %) | ||||||||||
拉丁美洲 |
260 | 394 | (134 | ) | (34) | %) | ||||||||||
世界其他地区 |
334 | 276 | 58 | 21 | % | |||||||||||
总计 |
$ | 2,731 | $ | 3,331 | $ | (600 | ) | (18) | %) | |||||||
|
Six Months Ended September 30, |
||||||||||||||||
(In thousands) |
2023 | 2022 | $ Change | % Change | ||||||||||||
United States |
$ | 1,396 | $ | 1,842 | $ | (446 | ) | (24 | %) | |||||||
Europe |
2,271 | 2,012 | 259 | 13 | % | |||||||||||
Asia |
1,208 | 1,438 | (230 | ) | (16 | %) | ||||||||||
Latin America |
747 | 1,444 | (697 | ) | (48 | %) | ||||||||||
Rest of the World |
536 | 578 | (42 | ) | (7 | %) | ||||||||||
Total |
$ | 6,158 | $ | 7,314 | $ | (1,156 | ) | (16 | %) | |||||||
| 六个月已结束 9月30日 |
||||||||||||||||
（以千计） |
2023 | 2022 | $ Change | % 变化 | ||||||||||||
美国 |
$ | 1,396 | $ | 1,842 | $ | (446 | ) | (24) | %) | |||||||
欧洲 |
2,271 | 2,012 | 259 | 13 | % | |||||||||||
亚洲 |
1,208 | 1,438 | (230) | ) | (16) | %) | ||||||||||
拉丁美洲 |
747 | 1,444 | (697) | ) | (48) | %) | ||||||||||
世界其他地区 |
536 | 578 | (42) | ) | (7) | %) | ||||||||||
总计 |
$ | 6158 | $ | 7,314 | $ | (1,156 | ) | (16) | %) | |||||||
SOURCE: Sonoma Pharmaceuticals, Inc.
来源：索诺玛制药公司